Our mission

Every year, millions of cancer patients receive a late or incorrect diagnosis, leading to invasive, unnecessary treatments that devastate lives and drain healthcare resources.

At 4fold, we are changing that by developing a low-cost, highly accurate diagnostics platform that analyses protein and DNA markers in a single test. We will catch cancers that other tests miss and dramatically reduce false alarms.

Our fully automated, sample-to-answer device will require minimal training, making it simple enough for staff at a GP surgery or pharmacy to use, yet engineered to scale for massive volumes in centralised labs.

We are eliminating the diagnostic errors that cost lives. Our mission is to deliver more accurate answers in an affordable way and save more than 100,000 lives every year.

The 4fold Bioscience diagnostic instrument

Our technology

We are currently deep in development, engineering a novel diagnostic platform that eliminates the trade-off between accessibility and accuracy. We plan to be more forthcoming with technical details later this year.

Who we are

  • Headshot of Ollie Miller, Co-founder

    Ollie Miller, Co-founder LinkedIn

    Drives the core technology of 4fold, developing our novel detection chemistry and hardware architecture. With a PhD in Biochemical Engineering and 15 years of experience translating advanced R&D into commercial products, Ollie previously led projects developing new sequencing platforms at Illumina.

  • Headshot of Duncan Brett, Co-founder

    Duncan Brett, Co-founder LinkedIn

    Leads the financial and commercial execution. Duncan brings over 20 years of experience in capital markets and financial advisory from Morgan Stanley, Goldman Sachs, Barclays Capital, and KPMG. With a BSc in Microbiology, Duncan translates scientific potential into rigorous, investor-ready commercial models.